Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 13/20 | 0.47 |
| ▸ | CPB1 | P15086 | 5/20 | 0.47 |
| ▸ | CPA1 | P15085 | 1/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24328256 | 1.00 | CPB2 (0.47) | CPB2CPB1CPA1ADRA2AADRA2B | |
| SCHEMBL5912570 | 0.76 | CPB2 (0.54) | CPB2CPB1CPA1HRH4HRH3 | |
| SCHEMBL19725072 | 0.73 | — | — | |
| SCHEMBL21686619 | 0.73 | CPA1 (0.51) | CPB2CPB1CPA1HRH4HRH3 | |
| SCHEMBL27408801 | 0.72 | HRH4 (0.48) | ADRA2AADRA2BADRA2CHRH4HRH3 | |
| SCHEMBL20520508 | 0.72 | CPB2 (0.47) | CPB2CPB1CPA1HRH4HRH3 | |
| SCHEMBL13346893 | 0.72 | CPB2 (0.54) | CPB2CPB1CPA1HRH4HRH3 | |
| SCHEMBL10079220 | 0.72 | CPB2 (0.54) | CPB2CPB1CPA1HRH4HRH3 | |
| SCHEMBL2102321 | 0.70 | ADRA2A (0.60) | CPA1ADRA2AADRA2BADRA2CHRH4 | |
| SCHEMBL5325231 | 0.70 | CPB2 (0.52) | CPB2CPB1CPA1HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399297-A1 | Novel Glutamine Analogs | JACOBIO PHARMACEUTICALS CO., LTD (CN) | 2023-12-14 | — | — | US | disclosed |
| WO-2022078416-A1 | NOVEL GLUTAMINE ANALOGS | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399297-A1 | Novel Glutamine Analogs | GLUL, GATD3, GLS | CPB2 3028/4885CPB1 2110/4885CPA1 2763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.